ARK-E021 5%
MA1001
Phase 2 small_molecule completed
Quick answer
ARK-E021 5% for Acne Vulgaris is a Phase 2 program (small_molecule) at VYNE Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- VYNE Therapeutics
- Indication
- Acne Vulgaris
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed